Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,09:00-12:00
R&D Strategies for Developing Innovative Drug Molecules Session
Stay tuned
09:00-09:15 Integrated Solutions for Oligonucleotide Therapeutic Development
Haiying He: Vice President, Head of Oligonucleotide & Peptide Discovery Chemistry, WuXi TIDES
09:15-09:30 Bioanalytical Strategies for Pharmacokinetic Assessment of Oligonucleotide Therapeutics
Jinlian Lu: Director, Drug Metabolism and Pharmacokinetics (DMPK), Laboratory Testing Division (LTD), WuXi AppTec
09:30-09:45 CNS Delivery Technologies in Large Animal (Non-Rodent) Species Enable DMPK Studies of Oligonucleotide Therapeutics
Jie Li: Associate Director, Drug Metabolism and Pharmacokinetics (DMPK), Laboratory Testing Division (LTD), WuXi AppTec
09:45-10:00 Nonclinical Safety Evaluation of Oligonucleotide Drugs
Yan Zhang: Director, Toxicology, Laboratory Testing Division (LTD), WuXi AppTec
10:00-10:15 Challenges and Solutions in Clinical Bioanalysis of Novel Oligonucleotide Drugs
Wenzhong Liang: Executive Director, Bioanalysis, Laboratory Testing Division (LTD), WuXi AppTec
10:15-10:30 Coffee Break
10:30-10:45 Efficient Synthesis Strategies for TPD
Anshu Wu: Senior Director, Research Chemistry Services, WuXi Chemistry, WuXi AppTec
10:45-11:00 Key Points and Safety Evaluation in Nonclinical Design of TPD
Robert Zhang: Vice President, Head of Toxicology, Laboratory Testing Division (LTD), WuXi AppTec
11:00-11:15 Integrated Solutions for PROTAC Development
Yu Lu: Vice President of API Early Phase Process R&D, WuXi STA
11:15-12:00 Roundtable
TBD (More guests to be confirmed…)